Abstract
High-quality biobanking within routine health services, through the use of existing health-care practices and infrastructure, with respect to safety and integrity of patients in line with the Swedish Biobank Act, enables large-scale collection of biological material at reasonable costs. Complementing the extensive information on myocardial infarction patients from a national registry gives unique opportunities for research focusing on better understanding of cardiovascular disease occurrence and prognosis, developing of new diagnostic methods, and personalized treatments with greater efficacy and fewer side effects.
Highlights
Already extensive research is being carried out using data from SWEDEHEART (5), which can be escalated by linking biobank data and samples to the registry
There are currently several regional initiatives where blood samples are collected as part of individual research projects in which phenotypic information is obtained from the SWEDEHEART registry
After approval by the Regional Ethical Review Board in Uppsala, the blood sample collection was started on 12 September 2011 at the Department of Cardiology, Uppsala University Hospital, in close collaboration with the Clinical Laboratory, Uppsala Clinical Research Center, and Uppsala Biobank
Summary
ISSN: 0300-9734 (Print) 2000-1967 (Online) Journal homepage: https://www.tandfonline.com/loi/iups.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.